Patent application number | Description | Published |
20100021402 | Compounds, Formulations, and Methods for Ameliorating Telangiectasis - Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an α-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours. | 01-28-2010 |
20100130502 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders - In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: | 05-27-2010 |
20100227867 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders - In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: | 09-09-2010 |
20110286945 | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging - Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an α2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly reduce skin sagging, creasing and/or wrinkling for at least about 8 hours. | 11-24-2011 |
20110288096 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING ERYTHEMA - Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and a pharmaceutically acceptable carrier. | 11-24-2011 |
20120277241 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders - In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: | 11-01-2012 |
20130172358 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders - In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: | 07-04-2013 |
20130172359 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders - In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: | 07-04-2013 |
20130197003 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING ERYTHEMA - Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and a pharmaceutically acceptable carrier. | 08-01-2013 |
20130243837 | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging - Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an α2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly reduce skin sagging, creasing and/or wrinkling for at least about 8 hours. | 09-19-2013 |
20140080836 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING ERYTHEMA - Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and a pharmaceutically acceptable carrier. | 03-20-2014 |
Patent application number | Description | Published |
20090060852 | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging - Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an α2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly reduce skin sagging, creasing and/or wrinkling for at least about 8 hours. | 03-05-2009 |
20110286945 | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging - Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an α2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly reduce skin sagging, creasing and/or wrinkling for at least about 8 hours. | 11-24-2011 |
20130243837 | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging - Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an α2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly reduce skin sagging, creasing and/or wrinkling for at least about 8 hours. | 09-19-2013 |
Patent application number | Description | Published |
20100021402 | Compounds, Formulations, and Methods for Ameliorating Telangiectasis - Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an α-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours. | 01-28-2010 |
20100130502 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders - In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: | 05-27-2010 |
20100227867 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders - In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: | 09-09-2010 |
20110118267 | Method and Kit for Treating or Preventing Psoriasis - Methods and kits for treating or preventing psoriasis or a symptom associated with psoriasis in a subject are described. The methods involve topical applications to the subject a therapeutically effective amount of an α2 adrenergic receptor agonist, such as brimonidine. | 05-19-2011 |
20110224215 | PRE-SURGICAL TREATMENT - The invention relates to a method of reducing post-surgical bleeding and/or bruising in a patient scheduled to be subjected to a surgical procedure and a patient that was subjected to a surgical procedure. The method involves topically applying to the area and the surrounding area of skin of the patient where the surgical procedure will be or was performed, a pharmaceutical composition comprising an effective amount of brimonidine or a pharmaceutically acceptable salt thereof, prior to performing the surgical procedure and/or following the surgical procedure. | 09-15-2011 |
20110288096 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING ERYTHEMA - Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and a pharmaceutically acceptable carrier. | 11-24-2011 |
20120277241 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders - In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: | 11-01-2012 |
20130172358 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders - In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: | 07-04-2013 |
20130172359 | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders - In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: | 07-04-2013 |
20130184283 | METHOD FOR TREATING PSORIASIS - Methods and kits for treating or preventing psoriasis or a symptom associated with psoriasis in a subject are described. The methods involve topical applications to the subject a therapeutically effective amount of an α2 adrenergic receptor agonist. | 07-18-2013 |
20130197003 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING ERYTHEMA - Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and a pharmaceutically acceptable carrier. | 08-01-2013 |
20140080836 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING ERYTHEMA - Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and a pharmaceutically acceptable carrier. | 03-20-2014 |